MM subgroup distribution in normal cell type–defined cluster after hierarchical clustering using vEDGs, v1LDGs, and v2LDGs
| Normal cell type–defined cluster . | Gene expression– defined MM subgroups . | P . | |||
|---|---|---|---|---|---|
| MM1 (n = 20) . | MM2 (n = 21) . | MM3 (n = 15) . | MM4 (n = 18) . | ||
| vEDGs (n = 22) | 3 | 1 | 5 | 13 | .000 05 |
| v1LDGs (n = 29) | 8 | 4 | 14 | 3 | .000 008 |
| v2LDGs (n = 20) | 6 | 14 | 0 | 0 | .000 001 |
| Normal cell type–defined cluster . | Gene expression– defined MM subgroups . | P . | |||
|---|---|---|---|---|---|
| MM1 (n = 20) . | MM2 (n = 21) . | MM3 (n = 15) . | MM4 (n = 18) . | ||
| vEDGs (n = 22) | 3 | 1 | 5 | 13 | .000 05 |
| v1LDGs (n = 29) | 8 | 4 | 14 | 3 | .000 008 |
| v2LDGs (n = 20) | 6 | 14 | 0 | 0 | .000 001 |
Gene expression–defined MM subgroups are as described in Zhan et al.42
Normal cell–defined cluster indicates MM cases clustering with CD19-enriched BCs using vEDGs (n = 22), CD138-enriched tonsil PCs using v1LDGs, or CD138-enriched bone marrow PCs using v2LDGs, defined by vEDGs as described in Figure 2. The MM cases within each normal cell type–defined cluster were separated based on whether the sample belonged to MM1, 2, 3, or 4.